MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
PAVmed Accounts Receivables 2011-2026 | PAVM
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PAVmed
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 K | 18 K | 61 K | 17 K | 200 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 K | 15 K | 62.2 K |
Quarterly Accounts Receivables PAVmed
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 K | 18 K | - | 219 K | 67 K | 61 K | 36 K | 41 K | 27 K | 17 K | 31 K | - | 89 K | 200 K | 200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 K | 3 K | 77.6 K |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
6.55 M | $ 9.23 | -1.6 % | $ 261 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
17.9 M | $ 3.46 | - | $ 130 M |  France |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 12.07 | - | $ 1.63 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 36.66 | -0.22 % | $ 5.46 K | USA |
 |
Globus Medical
GMED
|
679 M | $ 90.0 | 1.58 % | $ 12.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 1.81 | -4.74 % | $ 1.1 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.25 | -0.64 % | $ 712 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Inspire Medical Systems
INSP
|
120 M | $ 54.21 | 0.13 % | $ 1.59 B | USA |
 |
Integer Holdings Corporation
ITGR
|
346 M | $ 85.77 | 0.16 % | $ 2.98 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.78 | -1.0 % | $ 370 M | USA |
 |
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.01 | 1.85 % | $ 17.1 M | USA |
 |
LENSAR
LNSR
|
6.38 M | $ 5.82 | -1.27 % | $ 69.6 M | USA |
 |
Medtronic PLC
MDT
|
6.52 B | $ 86.12 | -0.19 % | $ 111 B | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.67 | -4.9 % | $ 28 M | USA |
 |
Align Technology
ALGN
|
996 M | $ 167.26 | -2.69 % | $ 12.5 B | USA |
 |
AxoGen
AXGN
|
26.2 M | $ 31.33 | -4.03 % | $ 1.44 B | USA |
 |
Orthofix Medical
OFIX
|
136 M | $ 11.58 | -1.61 % | $ 459 M |  Curacao |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Penumbra
PEN
|
190 M | $ 329.2 | -0.2 % | $ 12.8 B | USA |
 |
Insulet Corporation
PODD
|
161 M | $ 203.09 | -0.2 % | $ 14.3 B | USA |
 |
Sintx Technologies
SINT
|
178 K | $ 2.49 | -1.58 % | $ 6.91 M | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 4.03 | -2.42 % | $ 853 M | USA |
 |
Stryker Corporation
SYK
|
4.04 B | $ 331.18 | -0.34 % | $ 127 B | USA |
 |
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.59 | 0.69 % | $ 36.7 M | USA |
 |
Tactile Systems Technology
TCMD
|
43.9 M | $ 24.49 | -0.33 % | $ 560 M | USA |
 |
TELA Bio
TELA
|
10.3 M | $ 0.62 | -2.08 % | $ 29.1 M | USA |
 |
TransMedics Group
TMDX
|
84.3 M | $ 104.84 | 0.04 % | $ 3.56 B | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Tandem Diabetes Care
TNDM
|
165 M | $ 19.55 | 1.98 % | $ 1.33 B | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 9.61 | -0.98 % | $ 344 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |